Century Therapeutics IncNASDAQ:IPSC
- LAST PRICE2.9750
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.2100/ 2
- Ask / Lots4.7600/ 2
- Open / Previous Close0.0000 / 2.9750
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IPSC |
|---|---|---|
| 09:32 ET | 225 | 2.86 |
| 09:34 ET | 600 | 2.81 |
| 09:41 ET | 1592 | 2.81 |
| 09:48 ET | 1700 | 2.8 |
| 09:50 ET | 2000 | 2.76 |
| 09:52 ET | 5430 | 2.795 |
| 09:54 ET | 1100 | 2.77 |
| 09:56 ET | 6715 | 2.76 |
| 09:57 ET | 3338 | 2.81 |
| 10:01 ET | 321 | 2.77 |
| 10:06 ET | 300 | 2.75 |
| 10:08 ET | 100 | 2.82 |
| 10:10 ET | 200 | 2.795 |
| 10:14 ET | 100 | 2.8 |
| 10:17 ET | 100 | 2.78 |
| 10:19 ET | 200 | 2.8 |
| 10:26 ET | 100 | 2.78 |
| 10:28 ET | 400 | 2.82 |
| 10:37 ET | 4737 | 2.86 |
| 10:39 ET | 200 | 2.86 |
| 10:50 ET | 1300 | 2.86 |
| 10:51 ET | 200 | 2.87 |
| 10:53 ET | 300 | 2.88 |
| 10:55 ET | 100 | 2.87 |
| 10:57 ET | 700 | 2.9 |
| 11:02 ET | 300 | 2.895 |
| 11:06 ET | 200 | 2.87 |
| 11:09 ET | 900 | 2.91 |
| 11:11 ET | 100 | 2.92 |
| 11:15 ET | 900 | 2.955 |
| 11:18 ET | 250 | 2.955 |
| 11:22 ET | 200 | 2.92 |
| 11:26 ET | 914 | 2.98 |
| 11:27 ET | 500 | 2.96 |
| 11:29 ET | 300 | 2.9675 |
| 11:31 ET | 4605 | 2.92 |
| 11:33 ET | 300 | 2.94 |
| 11:36 ET | 4661 | 2.97 |
| 11:38 ET | 3000 | 2.9899 |
| 11:40 ET | 200 | 2.93 |
| 11:42 ET | 9368 | 2.9599 |
| 11:49 ET | 200 | 2.93 |
| 11:51 ET | 100 | 2.93 |
| 11:54 ET | 100 | 2.92 |
| 11:56 ET | 100 | 2.92 |
| 11:58 ET | 500 | 2.92 |
| 12:00 ET | 200 | 2.91 |
| 12:02 ET | 100 | 2.915 |
| 12:07 ET | 200 | 2.91 |
| 12:16 ET | 100 | 2.97 |
| 12:21 ET | 651 | 2.955 |
| 12:23 ET | 400 | 2.97 |
| 12:25 ET | 600 | 2.99 |
| 12:27 ET | 1770 | 2.99 |
| 12:30 ET | 400 | 3.01 |
| 12:38 ET | 400 | 3.03 |
| 12:39 ET | 500 | 3.03 |
| 12:41 ET | 1000 | 3.03 |
| 12:48 ET | 913 | 2.995 |
| 12:50 ET | 200 | 3 |
| 12:54 ET | 204 | 2.99 |
| 01:01 ET | 1500 | 2.97 |
| 01:06 ET | 600 | 2.98 |
| 01:14 ET | 100 | 2.98 |
| 01:15 ET | 500 | 2.97 |
| 01:19 ET | 900 | 3.01 |
| 01:28 ET | 200 | 3.01 |
| 01:48 ET | 800 | 3.03 |
| 01:51 ET | 216 | 3.0215 |
| 01:53 ET | 200 | 3.03 |
| 02:02 ET | 200 | 3.03 |
| 02:06 ET | 500 | 3.01 |
| 02:08 ET | 287 | 3.05 |
| 02:09 ET | 200 | 3.035 |
| 02:20 ET | 100 | 3.0295 |
| 02:24 ET | 100 | 3.02 |
| 02:29 ET | 100 | 3.0201 |
| 02:31 ET | 700 | 3.0425 |
| 02:33 ET | 500 | 3.02 |
| 02:38 ET | 100 | 3.05 |
| 02:45 ET | 561 | 3.035 |
| 02:47 ET | 500 | 3.03 |
| 02:54 ET | 2368 | 3.05 |
| 03:02 ET | 200 | 3.04 |
| 03:03 ET | 100 | 3.05 |
| 03:07 ET | 500 | 3.05 |
| 03:09 ET | 100 | 3.05 |
| 03:12 ET | 100 | 3.05 |
| 03:14 ET | 200 | 3.04 |
| 03:21 ET | 200 | 3.03 |
| 03:23 ET | 5100 | 3.05 |
| 03:25 ET | 3000 | 3.0201 |
| 03:32 ET | 100 | 3.02 |
| 03:34 ET | 404 | 3.0489 |
| 03:36 ET | 400 | 3.03 |
| 03:38 ET | 3049 | 3.01 |
| 03:39 ET | 100 | 2.965 |
| 03:48 ET | 100 | 3.02 |
| 03:50 ET | 3688 | 3 |
| 03:52 ET | 100 | 2.97 |
| 03:54 ET | 1005 | 2.93 |
| 03:56 ET | 5194 | 2.985 |
| 03:57 ET | 300 | 3.01 |
| 03:59 ET | 3800 | 2.975 |
Apr 12, 2024
DJ Century Therapeutics Price Target Cut to $9.00/Share From $10.00 by Piper Sandler, from 8:54AM ET on Friday Apr 12, 2024 by Dow Jones
8:54AM ET on Friday Apr 12, 2024 by Dow Jones
Apr 11, 2024
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics, from 7:00AM ET on Thursday Apr 11, 2024 by Dow Jones
7:00AM ET on Thursday Apr 11, 2024 by Dow Jones*DJ Century Therapeutics Strengthens Position In Autoimmune Disease With Strategic Pipeline Expansion Supported By $60 Million Private Placement And Acquisition Of Clade Therapeutics >IPSC, from 7:00AM ET on Thursday Apr 11, 2024 by Dow Jones
7:00AM ET on Thursday Apr 11, 2024 by Dow Jones
Apr 8, 2024
Mar 25, 2024
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors, from 7:00AM ET on Monday Mar 25, 2024 by Dow Jones
7:00AM ET on Monday Mar 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Century Therapeutics Inc | 240.1M | -1.3x | --- |
Inovio Pharmaceuticals Inc | 238.4M | -1.7x | --- |
XBiotech Inc | 240.9M | -9.8x | --- |
Adverum Biotechnologies Inc | 231.4M | -1.0x | --- |
Aldeyra Therapeutics Inc | 234.4M | -6.2x | --- |
Aeon Biopharma Inc | 247.1M | -6.6x | --- |
Company Information
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.
Contact Information
- Headquarters
- 25 N 38TH STREET, 11TH FLOORPHILADELPHIA, PA, United States 19104
- Phone
- 215-981-4000
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Jimenez
- President, Chief Executive Officer, Director
- Brent Pfeiffenberger
- Interim Principal Financial Officer, Senior Vice President - Finance and Operations
- Douglas Carr
- President - Research and Development
- Hyam Levitsky
- Chief Operations Officer, Head of Early Development
- Adrienne Farid
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $240.1M |
|---|---|
Revenue (TTM) | $2.2M |
Shares Outstanding | 80.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.30 |
Book Value | $3.06 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 107.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,556.87% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
